Pacritinib hydrochloride 是一种有效的野生型JAK2和JAK2V617F突变型抑制剂，IC50分别为 23 nM 和 19 nM。Pacritinib hydrochloride 也抑制FLT3及其突变型FLT3D835Y，IC50分别为 22 nM 和 6 nM。Pacritinib hydrochloride 可用于急性髓系白血病(AML)和骨髓纤维化(MF)的研究。

Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC 50 =23 nM) and JAK2 V617F mutant (IC 50 =19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC 50 =22 nM) and its mutant FLT3 D835Y (IC 50 =6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].

1228923-43-0

C28H32N4O3.xClH

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years